Patents by Inventor Philippe Jay

Philippe Jay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimeric enzymes and their applications
    Patent number: 11760982
    Abstract: The present invention relates to a chimeric enzyme comprising or consisting of at least one catalytic domain of a capping enzyme and at least one RNA-binding domain of a protein-RNA tethering system as well as its application for the production of an RNA molecule with a 5?-terminal cap.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: September 19, 2023
    Assignee: EUKARYS
    Inventor: Philippe Jaïs
  • Capping prone RNA polymerase enzymes and their applications
    Patent number: 9540671
    Abstract: The invention provides a chimeric enzyme comprising at least one catalytic domain of a RNA triphosphatase, at least one catalytic domain of a guanylyltransferase, at least one catalytic domain of a N7-guanine methyltransferase, and at least one catalytic domain of a DNA-dependant RNA polymerase. The invention also provides pharmaceutical composition comprising said chimeric enzyme and uses of said chimeric enzyme.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: January 10, 2017
    Assignee: EUKARYS
    Inventor: Philippe Jais
  • Capping-Prone RNA Polymerase Enzymes and Their Applications
    Publication number: 20150203888
    Abstract: The invention provides a chimeric enzyme comprising at least one catalytic domain of a RNA triphosphatase, at least one catalytic domain of a guanylyltransferase, at least one catalytic domain of a N7-guanine methyltransferase, and at least one catalytic domain of a DNA-dependant RNA polymerase. The invention also provides pharmaceutical composition comprising said chimeric enzyme and uses of said chimeric enzyme.
    Type: Application
    Filed: January 16, 2015
    Publication date: July 23, 2015
    Inventor: Philippe Jais
  • Capping-prone RNA polymerase enzymes and their applications
    Patent number: 8962292
    Abstract: The invention provides a chimeric enzyme comprising at least one catalytic domain of a RNA triphosphatase, at least one catalytic domain of a guanylyltransferase, at least one catalytic domain of a N7-guanine methyltransferase, and at least one catalytic domain of a DNA-dependant RNA polymerase. The invention also provides pharmaceutical composition comprising said chimeric enzyme and uses of said chimeric enzyme.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: February 24, 2015
    Assignee: EUKARYS
    Inventor: Philippe Jais
  • Capping-Prone RNA Polymerase Enzymes and Their Applications
    Publication number: 20130042334
    Abstract: The invention provides a chimeric enzyme comprising at least one catalytic domain of a RNA triphosphatase, at least one catalytic domain of a guanylyltransferase, at least one catalytic domain of a N7-guanine methyltransferase, and at least one catalytic domain of a DNA-dependant RNA polymerase. The invention also provides pharmaceutical composition comprising said chimeric enzyme and uses of said chimeric enzyme.
    Type: Application
    Filed: April 15, 2011
    Publication date: February 14, 2013
    Applicant: Eukarys
    Inventor: Philippe Jais
  • INHIBITORS OF PROGASTRIN-INDUCED REPRESSION OF ICAT FOR TREATING AND/OR PREVENTING COLORECTAL CANCER, ADENOMATOUS POLYPOSIS OR METASTASIS DISPLAYING PROGASTRIN-SECRETING CELLS AND CELLS IN WHICH THE BETA-CATENIN/TCF-MEDIATED TRANSCRIPTIONAL PATHWAY IS CONSTITUTIVELY ACTIVE
    Publication number: 20100209426
    Abstract: The present invention relates to inhibitors of progastrin induced repression of ICAT for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells and cells in which the beta-catenin/Tcf-4-mediated transcriptional pathway is constitutively active.
    Type: Application
    Filed: May 21, 2007
    Publication date: August 19, 2010
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC HERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERECHE SCIENTIFIQUE- CNRS, UNIVERSITE DE MONTPELLIER 1
    Inventors: Frederic Hollande, Dominique Joubert, Philippe Jay, Julie Pannequin, Nathalie Delaunay, Jean-Francois Bourgaux
  • VARIANTS AND EXONS OF THE GLYT1 TRANSPORTER
    Publication number: 20080201789
    Abstract: The present invention provides polypeptide and polynucleotide sequences for novel splice variants of the sodium and chloride-dependent glycine transporter type 1 (GlyT1). These polypeptides and polynucleotides are useful in the treatment and diagnosis of disorders such as neurological and psychiatric disorders including schizophrenia. The invention also provides antibodies directed specifically against these novel polypeptides, and kits comprising the herein-described polynucleotides, polypeptides, and/or antibodies.
    Type: Application
    Filed: March 18, 2008
    Publication date: August 21, 2008
    Applicant: SERONO GENETICS INSTITUTE S.A.
    Inventors: Gilbert Thill, Philippe Jais, Pascale Grel, Sandrine Mace
  • Variants and exons of the GlyT1 transporter
    Patent number: 7358066
    Abstract: The present invention provides polypeptide and polynucleotide sequences for novel splice variants of the sodium and chloride-dependent glycine transporter type 1 (GlyT1). These polypeptides and polynucleotides are useful in the treatment and diagnosis of disorders such as neurological and psychiatric disorders including schizophrenia. The invention also provides antibodies directed specifically against these novel polypeptides, and kits comprising the herein-described polynucleotides, polypeptides, and/or antibodies.
    Type: Grant
    Filed: July 22, 2002
    Date of Patent: April 15, 2008
    Assignee: Serono Genetics Institute S.A.
    Inventors: Gilbert Thill, Philippe Jais, Pascale Grel, Sandrine Mace
  • Novel variants and exons of the glyt1 transporter
    Publication number: 20050089855
    Abstract: The present invention provides polypeptide and polynucleotide sequences for novel splice variants of the sodium and chloride-dependent glycine transporter type 1 (GlyT1). These polypeptides and polynucleotides are useful in the treatment and diagnosis of disorders such as neurological and psychiatric disorders including schizophrenia. The invention also provides antibodies directed specifically against these novel polypeptides, and kits comprising the herein-described polynucleotides, polypeptides, and/or antibodies.
    Type: Application
    Filed: July 22, 2002
    Publication date: April 28, 2005
    Inventors: Gilbert ThilI, Philippe Jais, Pascale Grel, Sandrine Mace